July 10, 2013 — Epsilon Imaging Inc. announced a clinical study demonstrating EchoInsight for Cardio Oncology to be a high quality, efficient application for comprehensive assessment of left ventricle (LV) function. The study, presented at the ASE 2013 Scientific Sessions in Minneapolis, Minn., further indicated EchoInsight for Cardio Oncology facilitates monitoring of patients at risk for cardiotoxicity. EchoInsight for Cardio Oncology is a vendor neutral application designed to assist clinicians in improving confidence and workflow of study interpretation and reporting when monitoring oncology patients.
At ASE 2013, Jeanne DeCara, M.D., et al. from the University of Chicago Medicine presented, “Vendor Independent Software for Rapid Comprehensive Assessment of Changes in Left Ventricle Function During Serial Echocardiographic Studies.” The study analyzed serial comparison studies from 30 subjects. Ejection fraction (EF) and longitudinal strain were measured to monitor change in cardiac function. An experienced reader reviewed the studies on another commercially available solution, and an inexperienced reader used EchoInsight for Cardio Oncology for analysis. The inexperienced reader also completed analysis without EchoInsight for Cardio Oncology. Study results concluded that analysis and interpretation is faster using EchoInsight for Cardio Oncology when compared to the other commercial application, and offers consistent findings. EchoInsight for Cardio Oncology also slightly improved the inexperienced reader’s assessment of LV function change.
“Our study demonstrates EchoInsight for Cardio Oncology offers visualization and analysis that allows for quick, easy and accurate interpretation of LV function over time,” said DeCara. “EchoInsight is a promising software application that may assist in the follow-up of patients undergoing potentially cardiotoxic treatments, such as chemotherapy.”
For more information: www.epsilon-imaging.com
August 14, 2026 
